{"pmid":32476308,"title":"Empirical Treatment and Prevention of COVID-19.","text":["Empirical Treatment and Prevention of COVID-19.","The rapid spread of severe acute respiratory coronavirus syndrome 2 (SARS-CoV-2) in the population and throughout the cells within our body has been developing. Another major cycle of coronavirus disease 2019 (COVID-19), which is expected in the coming fall, could be even more severe than the current one. Therefore, effective countermeasures should be developed based on the already obtained clinical and research information about SARS-CoV-2. The aim of this review was to summarize the data on the empirical treatment of COVID-19 acquired during this SARS-CoV-2 infection cycle; this would aid the establishment of an appropriate healthcare policy to meet the challenges in the future. The infectious disease caused by SARS-CoV-2 is characterized by common cold along with hypersensitivity reaction. Thus, in addition to treating common cold, it is essential to minimize the exposure of cells to the virus and to mitigate the uncontrolled immune response. A proper combination of antiviral agents, immune modulators such as prednisolone, and anticoagulants such as heparin and anti-C5a antagonists could be employed to minimize lung damage and prevent systemic involvements. Finally, strategies to achieve population immunity against SARS-CoV-2 should be developed through understanding of the interaction between the immune system and the virus.","Infect Chemother","Shin, Hyoung Shik","32476308"],"abstract":["The rapid spread of severe acute respiratory coronavirus syndrome 2 (SARS-CoV-2) in the population and throughout the cells within our body has been developing. Another major cycle of coronavirus disease 2019 (COVID-19), which is expected in the coming fall, could be even more severe than the current one. Therefore, effective countermeasures should be developed based on the already obtained clinical and research information about SARS-CoV-2. The aim of this review was to summarize the data on the empirical treatment of COVID-19 acquired during this SARS-CoV-2 infection cycle; this would aid the establishment of an appropriate healthcare policy to meet the challenges in the future. The infectious disease caused by SARS-CoV-2 is characterized by common cold along with hypersensitivity reaction. Thus, in addition to treating common cold, it is essential to minimize the exposure of cells to the virus and to mitigate the uncontrolled immune response. A proper combination of antiviral agents, immune modulators such as prednisolone, and anticoagulants such as heparin and anti-C5a antagonists could be employed to minimize lung damage and prevent systemic involvements. Finally, strategies to achieve population immunity against SARS-CoV-2 should be developed through understanding of the interaction between the immune system and the virus."],"journal":"Infect Chemother","authors":["Shin, Hyoung Shik"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476308","source":"PubMed","week":"202023|Jun 01 - Jun 07","keywords":["covid-19","coronavirus","prevention","sars-cov-2","treatment"],"e_drugs":["Prednisolone","Heparin"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1668532089473990656,"score":9.490897,"similar":[{"pmid":32196426,"title":"Seasonality of Respiratory Viral Infections.","text":["Seasonality of Respiratory Viral Infections.","The seasonal cycle of respiratory viral diseases has been widely recognized for thousands of years, as annual epidemics of the common cold and influenza disease hit the human population like clockwork in the winter season in temperate regions. Moreover, epidemics caused by viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV) and the newly emerging SARS-CoV-2 occur during the winter months. The mechanisms underlying the seasonal nature of respiratory viral infections have been examined and debated for many years. The two major contributing factors are the changes in environmental parameters and human behavior. Studies have revealed the effect of temperature and humidity on respiratory virus stability and transmission rates. More recent research highlights the importance of the environmental factors, especially temperature and humidity, in modulating host intrinsic, innate, and adaptive immune responses to viral infections in the respiratory tract. Here we review evidence of how outdoor and indoor climates are linked to the seasonality of viral respiratory infections. We further discuss determinants of host response in the seasonality of respiratory viruses by highlighting recent studies in the field. Expected final online publication date for the Annual Review of Virology, Volume 7 is September 29, 2020. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.","Annu Rev Virol","Moriyama, Miyu","Hugentobler, Walter J","Iwasaki, Akiko","32196426"],"abstract":["The seasonal cycle of respiratory viral diseases has been widely recognized for thousands of years, as annual epidemics of the common cold and influenza disease hit the human population like clockwork in the winter season in temperate regions. Moreover, epidemics caused by viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV) and the newly emerging SARS-CoV-2 occur during the winter months. The mechanisms underlying the seasonal nature of respiratory viral infections have been examined and debated for many years. The two major contributing factors are the changes in environmental parameters and human behavior. Studies have revealed the effect of temperature and humidity on respiratory virus stability and transmission rates. More recent research highlights the importance of the environmental factors, especially temperature and humidity, in modulating host intrinsic, innate, and adaptive immune responses to viral infections in the respiratory tract. Here we review evidence of how outdoor and indoor climates are linked to the seasonality of viral respiratory infections. We further discuss determinants of host response in the seasonality of respiratory viruses by highlighting recent studies in the field. Expected final online publication date for the Annual Review of Virology, Volume 7 is September 29, 2020. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates."],"journal":"Annu Rev Virol","authors":["Moriyama, Miyu","Hugentobler, Walter J","Iwasaki, Akiko"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32196426","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1146/annurev-virology-012420-022445","topics":["Transmission"],"weight":1,"_version_":1666138490075611137,"score":175.55247},{"pmid":32299148,"title":"Considerations for obesity, vitamin D, and physical activity amidst the COVID-19 pandemic.","text":["Considerations for obesity, vitamin D, and physical activity amidst the COVID-19 pandemic.","As the biomedical community races to disentangle the unknowns associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the virus responsible for causing coronavirus disease (COVID-19) - the link between diminished immune function and individuals with obesity raises important questions about the possibility for greater viral pathogenicity in this population. Increased adiposity may undermine the pulmonary microenvironment wherein viral pathogenesis and immune cell trafficking could contribute to a maladaptive cycle of local inflammation and secondary injury. A further challenge to those with obesity during the current pandemic may involve vitamin D deficiency/insufficiency. In the interest of personal and public health, we caution decision/policy makers alike not to pin all hope on a proverbial 'silver bullet.' Until further breakthroughs emerge, we should remember that modifiable lifestyle factors like diet and physical activity should not be marginalized. Decades of empirical evidence supports both as key factors promoting health and wellness.","Obesity (Silver Spring)","Carter, Stephen J","Baranauskas, Marissa N","Fly, Alyce D","32299148"],"abstract":["As the biomedical community races to disentangle the unknowns associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the virus responsible for causing coronavirus disease (COVID-19) - the link between diminished immune function and individuals with obesity raises important questions about the possibility for greater viral pathogenicity in this population. Increased adiposity may undermine the pulmonary microenvironment wherein viral pathogenesis and immune cell trafficking could contribute to a maladaptive cycle of local inflammation and secondary injury. A further challenge to those with obesity during the current pandemic may involve vitamin D deficiency/insufficiency. In the interest of personal and public health, we caution decision/policy makers alike not to pin all hope on a proverbial 'silver bullet.' Until further breakthroughs emerge, we should remember that modifiable lifestyle factors like diet and physical activity should not be marginalized. Decades of empirical evidence supports both as key factors promoting health and wellness."],"journal":"Obesity (Silver Spring)","authors":["Carter, Stephen J","Baranauskas, Marissa N","Fly, Alyce D"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32299148","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1002/oby.22838","keywords":["body mass index","cardiopulmonary","inflammation","influenza","prevention"],"e_drugs":["Vitamin D"],"topics":["Prevention"],"weight":1,"_version_":1666138493270622208,"score":170.75409},{"pmid":32353634,"pmcid":"PMC7185015","title":"COVID-19: Immunology and treatment options.","text":["COVID-19: Immunology and treatment options.","The novel coronavirus SARS-CoV2 causes COVID-19, a pandemic threatening millions. As protective immunity does not exist in humans and the virus is capable of escaping innate immune responses, it can proliferate, unhindered, in primarily infected tissues. Subsequent cell death results in the release of virus particles and intracellular components to the extracellular space, which result in immune cell recruitment, the generation of immune complexes and associated damage. Infection of monocytes/macrophages and/or recruitment of uninfected immune cells can result in massive inflammatory responses later in the disease. Uncontrolled production of pro-inflammatory mediators contributes to ARDS and cytokine storm syndrome. Antiviral agents and immune modulating treatments are currently being trialled. Understanding immune evasion strategies of SARS-CoV2 and the resulting delayed massive immune response will result in the identification of biomarkers that predict outcomes as well as phenotype and disease stage specific treatments that will likely include both antiviral and immune modulating agents.","Clin Immunol","Felsenstein, Susanna","Herbert, Jenny A","McNamara, Paul S","Hedrich, Christian M","32353634"],"abstract":["The novel coronavirus SARS-CoV2 causes COVID-19, a pandemic threatening millions. As protective immunity does not exist in humans and the virus is capable of escaping innate immune responses, it can proliferate, unhindered, in primarily infected tissues. Subsequent cell death results in the release of virus particles and intracellular components to the extracellular space, which result in immune cell recruitment, the generation of immune complexes and associated damage. Infection of monocytes/macrophages and/or recruitment of uninfected immune cells can result in massive inflammatory responses later in the disease. Uncontrolled production of pro-inflammatory mediators contributes to ARDS and cytokine storm syndrome. Antiviral agents and immune modulating treatments are currently being trialled. Understanding immune evasion strategies of SARS-CoV2 and the resulting delayed massive immune response will result in the identification of biomarkers that predict outcomes as well as phenotype and disease stage specific treatments that will likely include both antiviral and immune modulating agents."],"journal":"Clin Immunol","authors":["Felsenstein, Susanna","Herbert, Jenny A","McNamara, Paul S","Hedrich, Christian M"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353634","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.clim.2020.108448","topics":["Treatment","Diagnosis","Mechanism"],"weight":1,"_version_":1666138495705415681,"score":169.14993},{"pmid":32395418,"pmcid":"PMC7211915","title":"An Update on Current Therapeutic Drugs Treating COVID-19.","text":["An Update on Current Therapeutic Drugs Treating COVID-19.","The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeutic agents against the virus. Current clinical management includes infection prevention and control measures and supportive care including supplemental oxygen and mechanical ventilatory support. Evolving research and clinical data regarding the virologic SARS-CoV-2 suggest a potential list of repurposed drugs with appropriate pharmacological effects and therapeutic efficacies in treating COVID-19 patients. In this review, we will update and summarize the most common and plausible drugs for the treatment of COVID-19 patients. These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and oseltamivir), and supporting agents (Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others. We hope that this review will provide useful and most updated therapeutic drugs to prevent, control, and treat COVID-19 patients until the approval of vaccines and specific drugs targeting SARS-CoV-2.","Curr Pharmacol Rep","Wu, Renyi","Wang, Lujing","Kuo, Hsiao-Chen Dina","Shannar, Ahmad","Peter, Rebecca","Chou, Pochung Jordan","Li, Shanyi","Hudlikar, Rasika","Liu, Xia","Liu, Zhigang","Poiani, George J","Amorosa, Louis","Brunetti, Luigi","Kong, Ah-Ng","32395418"],"abstract":["The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeutic agents against the virus. Current clinical management includes infection prevention and control measures and supportive care including supplemental oxygen and mechanical ventilatory support. Evolving research and clinical data regarding the virologic SARS-CoV-2 suggest a potential list of repurposed drugs with appropriate pharmacological effects and therapeutic efficacies in treating COVID-19 patients. In this review, we will update and summarize the most common and plausible drugs for the treatment of COVID-19 patients. These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and oseltamivir), and supporting agents (Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others. We hope that this review will provide useful and most updated therapeutic drugs to prevent, control, and treat COVID-19 patients until the approval of vaccines and specific drugs targeting SARS-CoV-2."],"journal":"Curr Pharmacol Rep","authors":["Wu, Renyi","Wang, Lujing","Kuo, Hsiao-Chen Dina","Shannar, Ahmad","Peter, Rebecca","Chou, Pochung Jordan","Li, Shanyi","Hudlikar, Rasika","Liu, Xia","Liu, Zhigang","Poiani, George J","Amorosa, Louis","Brunetti, Luigi","Kong, Ah-Ng"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32395418","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s40495-020-00216-7","keywords":["anakinra","azithromycin","covid-19","chloroquine","convalescent plasma","epoprostenol","favipiravir","hydroxychloroquine","lopinavir","methylprednisolone","nitric oxide","oseltamivir","remdesivir","sar-cov-2","sarilumab","sirolimus","tocilizumab","traditional chinese medicine","umifenovir","vitamin c"],"locations":["Azithromycin"],"topics":["Treatment"],"weight":1,"_version_":1666627827806502913,"score":168.10756},{"pmid":32325767,"title":"COVID-19 Drug Discovery Using Intensive Approaches.","text":["COVID-19 Drug Discovery Using Intensive Approaches.","Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable.","Int J Mol Sci","Asai, Ayumu","Konno, Masamitsu","Ozaki, Miyuki","Otsuka, Chihiro","Vecchione, Andrea","Arai, Takahiro","Kitagawa, Toru","Ofusa, Ken","Yabumoto, Masami","Hirotsu, Takaaki","Taniguchi, Masateru","Eguchi, Hidetoshi","Doki, Yuichiro","Ishii, Hideshi","32325767"],"abstract":["Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable."],"journal":"Int J Mol Sci","authors":["Asai, Ayumu","Konno, Masamitsu","Ozaki, Miyuki","Otsuka, Chihiro","Vecchione, Andrea","Arai, Takahiro","Kitagawa, Toru","Ofusa, Ken","Yabumoto, Masami","Hirotsu, Takaaki","Taniguchi, Masateru","Eguchi, Hidetoshi","Doki, Yuichiro","Ishii, Hideshi"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32325767","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.3390/ijms21082839","keywords":["covid-19","coronavirus","drug discovery","drug repositioning","infection"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138494548836352,"score":159.27347}]}